Windward Bio has dosed the first patients in a Phase 2 study of HBM9378/WIN378 for chronic obstructive pulmonary disease, according ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE